In fact, in addition to personalized treatments considering the CFTR mutation of the CF patients under treatment, different dosage of the anti-miRNA components can be tailored depending on the pattern of CFTR-regulating miRNAs upregulated in the CF patients subject to further optimization of the intervention based on these precision medicines. The gene discussed is CFTR; the disease is cystic fibrosis.